leukemia news from FierceBiotech
News
Antisoma buys Xanthus for $52M
Looking to boost its pipeline, the U.K.'s Antisoma is paying $52 million for Boston oncology company Xanthus Pharmaceutical. Antisoma gains three drug candidates:Xanafide, which is in Phase III trial Read more...
EUSA Pharma spins off assets as it narrows focus
The transatlantic EUSA Pharma has spun off its monoclonal antibody research operation along with a development program for leukemia as it narrows its focus to late-stage drug development and Read more...
Aldagen gets $18.4M in fourth round
With the help of Intersouth Partners, Tullis-Dickerson, Harbert Venture Partners and The Aurora Funds, stem cell technology company Aldagen has closed an $18.4 million fourth round of funding. The Read more...
SPOTLIGHT: Genta restructures
restructuresWith the FDA unwilling to budge on its decision to demand more data before it approves Read more...
Cephalon, investors await FDA Treanda decision
After seeing its stock price shed about a third of its value since last summer, Cephalon is keeping its fingers crossed that tomorrow's scheduled regulatory decision on its cancer drug Treanda can Read more...
Biogen CEO spells out interest in biotech buyout
Just days after scornfully assessing a field of weak-kneed pharma Read more...
FDA extends review time for Genta's appeal
Genta is going to have to wait a little longer before it gets final word on its appeal of the FDA's rejection Read more...
FDA removes hold on Vion's late-stage cancer trial
Vion Pharmaceuticals has received a green light from the FDA to resume studying the cancer drug Cloretazine as regulators removed a clinical hold on a Phase III trial of the therapy. The late stage Read more...
Novacea slows down development program for AQ4N
Novacea, which is burning through $17 million to $19 million this year, says it will scale back on the development of AQ4N, shelving a clinical trial in acute lymphoblastic leukemia and delaying a Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets